ATE347897T1 - Lang wirksame, parasiten-abtötende zubereitung enthaltend eine salicylanilid verbindung, eine polymere verbindung und mindestens eine weitere parasiten-abtötende verbindung - Google Patents

Lang wirksame, parasiten-abtötende zubereitung enthaltend eine salicylanilid verbindung, eine polymere verbindung und mindestens eine weitere parasiten-abtötende verbindung

Info

Publication number
ATE347897T1
ATE347897T1 AT03702765T AT03702765T ATE347897T1 AT E347897 T1 ATE347897 T1 AT E347897T1 AT 03702765 T AT03702765 T AT 03702765T AT 03702765 T AT03702765 T AT 03702765T AT E347897 T1 ATE347897 T1 AT E347897T1
Authority
AT
Austria
Prior art keywords
compound
parasitic
killing
acting
long
Prior art date
Application number
AT03702765T
Other languages
German (de)
English (en)
Inventor
William Blakely
Lillian Cromie
Sean Duffy
Original Assignee
Norbrook Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norbrook Lab Ltd filed Critical Norbrook Lab Ltd
Application granted granted Critical
Publication of ATE347897T1 publication Critical patent/ATE347897T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AT03702765T 2002-02-28 2003-02-12 Lang wirksame, parasiten-abtötende zubereitung enthaltend eine salicylanilid verbindung, eine polymere verbindung und mindestens eine weitere parasiten-abtötende verbindung ATE347897T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0204712A GB2386066A (en) 2002-02-28 2002-02-28 Long-acting parasiticidal composition with improved bioavailability comprising a salicylanilide, a further anti-parasitic compound & a polymeric species

Publications (1)

Publication Number Publication Date
ATE347897T1 true ATE347897T1 (de) 2007-01-15

Family

ID=9931978

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03702765T ATE347897T1 (de) 2002-02-28 2003-02-12 Lang wirksame, parasiten-abtötende zubereitung enthaltend eine salicylanilid verbindung, eine polymere verbindung und mindestens eine weitere parasiten-abtötende verbindung

Country Status (23)

Country Link
US (1) US9289380B2 (cg-RX-API-DMAC7.html)
EP (1) EP1478372B1 (cg-RX-API-DMAC7.html)
JP (1) JP4480400B2 (cg-RX-API-DMAC7.html)
AP (1) AP1977A (cg-RX-API-DMAC7.html)
AR (1) AR038852A1 (cg-RX-API-DMAC7.html)
AT (1) ATE347897T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003205887B2 (cg-RX-API-DMAC7.html)
BR (1) BR0307974B1 (cg-RX-API-DMAC7.html)
CA (1) CA2476520C (cg-RX-API-DMAC7.html)
CO (1) CO5611154A2 (cg-RX-API-DMAC7.html)
CR (1) CR7429A (cg-RX-API-DMAC7.html)
CY (1) CY1107530T1 (cg-RX-API-DMAC7.html)
DE (1) DE60310377T2 (cg-RX-API-DMAC7.html)
DK (1) DK1478372T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP045320A (cg-RX-API-DMAC7.html)
ES (1) ES2275076T3 (cg-RX-API-DMAC7.html)
GB (1) GB2386066A (cg-RX-API-DMAC7.html)
MX (1) MXPA04007996A (cg-RX-API-DMAC7.html)
NZ (1) NZ534704A (cg-RX-API-DMAC7.html)
PT (1) PT1478372E (cg-RX-API-DMAC7.html)
SI (1) SI1478372T1 (cg-RX-API-DMAC7.html)
WO (1) WO2003072113A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200406782B (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002952597A0 (en) * 2002-11-11 2002-11-28 Schering-Plough Pty. Limited Topical parasiticide formulations and methods of treatment
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
RU2005133427A (ru) 2003-03-31 2006-04-27 Алза Корпорейшн (Us) Безводные однофазные носители и препараты с использованием таких носителей
US7666444B2 (en) 2004-02-02 2010-02-23 Wyeth Antiparasitic composition
EP1824474A1 (en) * 2004-12-10 2007-08-29 Bayer HealthCare AG Anthelmintic composition
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
ES2351527T3 (es) 2006-05-30 2011-02-07 Intarcia Therapeutics, Inc Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración.
KR101200728B1 (ko) 2006-08-09 2012-11-13 인타르시아 세라퓨틱스 인코포레이티드 삼투성 전달 시스템 및 피스톤 조립체
RU2440097C2 (ru) 2007-04-23 2012-01-20 Интарсия Терапьютикс, Инк. Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
HRP20171801T1 (hr) 2009-09-28 2017-12-29 Intarcia Therapeutics, Inc. Brzo uspostavljanje i/ili brzo završavanje uglavnom stabilne primjene lijeka
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
FR2991173B1 (fr) 2012-06-04 2015-11-06 Virbac Composition veterinaire a administration cutanee a base d'oxyclozanide
CN105579029B (zh) * 2013-09-30 2019-03-05 硕腾服务有限责任公司 长效螺异恶唑啉制剂
ES2661000T3 (es) 2014-09-12 2018-03-27 Antibiotx A/S Uso antibacteriano de salicilanilidas halogenadas
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
GB201604484D0 (en) * 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
RU2760007C2 (ru) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Полипептиды, селективные к рецепторам глюкагона, и способы их применения
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
BR112022013784A2 (pt) 2020-01-13 2022-10-11 Durect Corp Sistemas de distribuição de fármacos de liberação prolongada com impurezas reduzidas e métodos relacionados
JP2024503402A (ja) 2021-01-12 2024-01-25 デュレクト コーポレーション 徐放性薬物送達システム及び関連の方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3950360A (en) 1972-06-08 1976-04-13 Sankyo Company Limited Antibiotic substances
DE2263509C2 (de) 1972-12-27 1981-12-24 Rudolf Dr. 6380 Bad Homburg Kürner Deodorant
US4005218A (en) * 1975-03-18 1977-01-25 Janssen Pharmaceutica N.V. Antiparasitic salicylanilide derivatives
SE434277B (sv) * 1976-04-19 1984-07-16 Merck & Co Inc Sett att framstella nya antihelmintiskt verkande foreningar genom odling av streptomyces avermitilis
US4206205A (en) * 1977-10-03 1980-06-03 Merck & Co., Inc. Monosaccharide and aglycone derivatives of C-076
US4199569A (en) * 1977-10-03 1980-04-22 Merck & Co., Inc. Selective hydrogenation products of C-076 compounds and derivatives thereof
US4173571A (en) * 1977-12-19 1979-11-06 Merck & Co., Inc. 13-Halo and 13-deoxy derivatives of C-076 compounds
US4171314A (en) * 1977-12-19 1979-10-16 Merck & Co., Inc. 13-Halo and 13-deoxy C-076 compounds
US4128632A (en) * 1978-02-13 1978-12-05 Merck & Co., Inc. Solubilization of Rafoxanide
OA06863A (fr) 1980-08-04 1983-02-28 Merck & Co Inc Solubilisation de l'invermectine dans l'eau.
NZ210505A (en) 1983-12-22 1988-06-30 Merck & Co Inc Parasiticidal compositions containing avermectin or milbemycin derivatives
GB8727157D0 (en) * 1987-11-19 1987-12-23 Wellcome Found Pharmaceutical formulations
NZ223200A (en) * 1988-01-15 1989-01-06 Ancare Distributors Anthelmintic compositions containing 2',5-dicloro-4'-nitrosalicylanilide and non aqueous carrier
US5273805A (en) * 1991-08-05 1993-12-28 Minnesota Mining And Manufacturing Company Structured flexible carrier web with recess areas bearing a layer of silicone on predetermined surfaces
NZ335166A (en) 1999-04-14 2001-11-30 Ashmont Holdings Ltd Anthelmintic composition containing triclabendazole in at least one solvent
CN1054504C (zh) 1993-03-15 2000-07-19 科尔加特·帕尔莫利弗公司 洁牙剂
PL174488B1 (pl) 1993-05-10 1998-08-31 Merck & Co Inc Preparat do zwalczania pasożytów zwierząt oraz sposób wytwarzania preparatu do zwalczania pasożytów zwierząt
DE69432985D1 (de) 1993-06-15 2003-09-04 Australian Nat University Acto Synergistische anthelmintische zusammensetzungen gegen fasciola hepatica und andere fascola spezien
NZ248486A (en) * 1993-08-24 1996-07-26 Ashmont Holdings Limited Subst Stable anthelmintic formulation containing closantel and one or more avermectins or milbemycins in a glycol based solvent
WO1995016447A1 (en) 1993-12-13 1995-06-22 Michael Hilary Burke Anthelmintic composition containing rafoxanide and fenbendazole
FR2739778B1 (fr) 1995-10-13 1997-12-12 Virbac Lab Formulation topique destinee a traiter la maladie de la douve du foie chez l'animal
US5773422A (en) * 1996-01-29 1998-06-30 Komer; Gene Avermectin formulation
US6193989B1 (en) * 1997-03-21 2001-02-27 Biogenesis S.A. Long acting injectable parasiticidal composition and the process for its preparation
US6340672B1 (en) 2000-02-16 2002-01-22 Phoenix Scientific, Inc. Parasiticidal formulation and a method of making this formulation
AUPQ875700A0 (en) * 2000-07-13 2000-08-03 Reflex Research Limited Combination compositions
AUPR510001A0 (en) 2001-05-18 2001-06-14 Jupitar Pty Ltd Formulation and method

Also Published As

Publication number Publication date
AR038852A1 (es) 2005-01-26
GB2386066A (en) 2003-09-10
MXPA04007996A (es) 2004-11-26
AU2003205887B2 (en) 2007-02-15
NZ534704A (en) 2007-02-23
BR0307974B1 (pt) 2014-10-21
DE60310377T2 (de) 2007-10-31
ECSP045320A (es) 2004-11-26
AP2004003142A0 (en) 2004-09-30
US9289380B2 (en) 2016-03-22
SI1478372T1 (sl) 2007-04-30
GB0204712D0 (en) 2002-04-17
JP4480400B2 (ja) 2010-06-16
CY1107530T1 (el) 2013-03-13
CA2476520C (en) 2009-08-11
AP1977A (en) 2009-03-19
WO2003072113A1 (en) 2003-09-04
ZA200406782B (en) 2005-07-27
CA2476520A1 (en) 2003-09-04
EP1478372A1 (en) 2004-11-24
DK1478372T3 (da) 2007-04-10
AU2003205887A1 (en) 2003-09-09
DE60310377D1 (de) 2007-01-25
JP2005525355A (ja) 2005-08-25
BR0307974A (pt) 2004-12-21
CO5611154A2 (es) 2006-02-28
EP1478372B1 (en) 2006-12-13
PT1478372E (pt) 2007-01-31
ES2275076T3 (es) 2007-06-01
CR7429A (es) 2006-02-06
US20050118221A1 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
ATE347897T1 (de) Lang wirksame, parasiten-abtötende zubereitung enthaltend eine salicylanilid verbindung, eine polymere verbindung und mindestens eine weitere parasiten-abtötende verbindung
EP1371708A4 (en) ORGANIC ELECTROLUMINESCENCE DEVICE, LUMINESCENT MATERIAL, AND ORGANIC COMPOUND
IS7946A (is) Lyf
HU0103988D0 (en) New compounds with pharmaceutical activity
HUP0400159A3 (en) Anthranilic acid amides with a heteroarylsulfonyl side chain, method for the production thereof, use thereof and pharmaceutical compositions containing them
IS7491A (is) Benzoxazínon-afleidd efnasambönd, framleiðsla þeirra og notkun sem lyf
HU0103987D0 (en) New compounds with pharmaceutical activity
AU2002316939A1 (en) Anthranilic acid amides with a heteroarylsulfonyl side chain, and use thereof as antiarrhythmic active substances
DE60207335D1 (de) Zweiteiliger Drehbefestiger
AU2003266161A8 (en) High concentration topical insecticide
PL394600A1 (pl) Związek winyloazacykloalkanowy, sposób jego wytwarzania i jego zastosowanie oraz kompozycja farmaceutyczna
AU2001267583A1 (en) Biphenylcarboxylic acid amides, production thereof and use thereof as medicaments
HUP0401092A3 (en) 5-halogen-6-phenyl-7-fluoralkylamino-triazolopyrimidines as fungicides, preparation and use thereof
EE200100615A (et) Mikrograanul, selle valmistamismeetod ja farmatseutiline preparaat
EP1559703A4 (en) NATURAL COMPOUND FOR THE TREATMENT OF DIABETES, THEIR PREPARATION AND USE
ZA200602788B (en) Amidomethyl-substituted 2-(4-sulfonilamino)-3-hidroxy-3,4-dihydro-2H-chromen-6-YL-derivatives and drugs containing said compounds
ATE294804T1 (de) Pharmazeutische zusammensetzung enthaltend ein farnesyl-transferase hemmenden 1,2-annellierten chinolin enantiomer
GB0125617D0 (en) Photostabilised organic material
PT1053224E (pt) Bifenilsulfonilcianamida, processo para a sua preparacao e sua utilizacao como medicamento
PL344309A1 (en) Novel antiestrogens, a method for the production thereof, and their pharmaceutical application
PT1157020E (pt) 1,2,3,4,5,6-hexa-hidro-2,6-metano-3-benzazocin-10-ois substituidos processo para a sua preparacao e sua utilizacao como medicamentos
HRP20040691A2 (en) 2'-halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine and the use thereof as a drug
DE50208568D1 (de) Silage-Schneidzange
HUP0200381A3 (en) Sieve with slit or split shaped gaps
ZA200309512B (en) Crystalline form a phenylethanolamine, the preparation thereof and pharmaceutical compositions comprising the same.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1478372

Country of ref document: EP